EXEL Exelixis Inc

$40.09

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Exelixis Inc

Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.

Website: https://www.exelixis.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
939767
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA, US
Valuation
Market Cap
$9.97B
P/E Ratio
20.56
PEG Ratio
2.27
Price to Book
4.44
Performance
EPS
$1.76
Dividend Yield
—
Profit Margin
24.00%
ROE
23.10%
Technicals
50D MA
$36.30
200D MA
$31.23
52W High
$40.02
52W Low
$20.14
Fundamentals
Shares Outstanding
276M
Target Price
$37.95
Beta
0.57

EXEL EPS Estimates vs Actual

● Estimated
● Actual

EXEL News & Sentiment

Oct 01, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
Sep 30, 2025 • Motley Fool SOMEWHAT-BULLISH
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Both should have significant catalysts by the end of the decade.
Sep 25, 2025 • GlobeNewswire SOMEWHAT-BULLISH
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
NEW YORK, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- LB Pharmaceuticals Inc ( "LB Pharmaceuticals" or the "Company" ) ( Nasdaq: LBRX ) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September ...
Sep 25, 2025 • Benzinga SOMEWHAT-BULLISH
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani - LB Pharmaceuticals ( NASDAQ:LBRX )
NEW YORK, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- LB Pharmaceuticals Inc ( "LB Pharmaceuticals" or the "Company" ) ( NASDAQ: LBRX ) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September ...
Sep 15, 2025 • Benzinga SOMEWHAT-BULLISH
Peering Into Exelixis's Recent Short Interest - Exelixis ( NASDAQ:EXEL )
Exelixis's EXEL short interest as a percent of float has risen 4.39% since its last report. According to exchange reported data, there are now 17.63 million shares sold short, which is 9.03% of all regular shares that are available for trading.
Sep 08, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Here's Why Exelixis ( EXEL ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sentiment Snapshot

Average Sentiment Score:

0.219
50 articles with scored sentiment

Overall Sentiment:

Bullish

EXEL Reported Earnings

Apr 28, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.37
  • Whisper: —
  • Surprise %: 0.0%
Feb 04, 2025
Dec 31, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $0.55
  • Estimate: $0.49
  • Whisper: —
  • Surprise %: 11.8%
Oct 29, 2024
Sep 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.40
  • Estimate: $0.35
  • Whisper: —
  • Surprise %: 14.3%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.47 Surprise
  • Reported EPS: $0.77
  • Estimate: $0.30
  • Whisper: —
  • Surprise %: 156.7%
Apr 30, 2024
Mar 31, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $0.20
  • Estimate: $0.24
  • Whisper: —
  • Surprise %: -16.7%
Feb 06, 2024
Dec 31, 2023 (Post market)
0.06 Surprise
  • Reported EPS: $0.27
  • Estimate: $0.21
  • Whisper: —
  • Surprise %: 28.6%
Nov 01, 2023
Sep 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $0.10
  • Estimate: $0.10
  • Whisper: —
  • Surprise %: 0.0%
Aug 01, 2023
Jun 30, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $0.25
  • Estimate: $0.16
  • Whisper: —
  • Surprise %: 56.2%
May 09, 2023
Mar 31, 2023 (Post market)
-0.03 Surprise
  • Reported EPS: $0.12
  • Estimate: $0.15
  • Whisper: —
  • Surprise %: -20.0%

Financials